Unknown

Dataset Information

Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial.


ABSTRACT:

Background

Despite improvement in the standard of care (SOC) for hospitalized COVID-19 patients, rates of morbidity and mortality remain high. There continues to be a need for easily available and cost-effective treatments. Colchicine and rosuvastatin are both safe and well-studied medications with anti-inflammatory and other pleiotropic effects that may provide additional benefits to hospitalized COVID-19 patients.

Methods and results

The Colchicine/Statin for the Prevention of COVID-19 Complications (COLSTAT) trial is a pragmatic, open-label, multicenter, randomized trial comparing the combination of colchicine and rosuvastatin in addition to SOC to SOC alone in hospitalized COVID-19 patients. Four centers in the Yale New Haven Health network will enroll a total of 466 pat

SUBMITTER: Shah T 

PROVIDER: S-EPMC8397504 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature